Across TCGA pan-cancer cohorts, ASB7 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ASB7 data layer compared with 20 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ASB7 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ASB7 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

PDAC, LUAD, and LSCC are the cancer types where ASB7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.211	0.953	.010	18	view →
LUAD	DFS	Median	All	0.383	1.000	.010	8	view →
LSCC	DFS	Tertile	II,III,IV	0.982	0.656	.010	7	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: ASB7 tumor-vs-normal RNA expression · all ASB7 data types